Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Verzenio Improves Overall Survival in Hormone Receptor-Positive, HER2-Negative, Advanced Stage Breast Cancer

    Verzenio Improves Overall Survival in Hormone Receptor-Positive, HER2-Negative, Advanced Stage Breast Cancer

    FromBreastcancer.org Podcast

    Start listeningView podcast show

    Verzenio Improves Overall Survival in Hormone Receptor-Positive, HER2-Negative, Advanced Stage Breast Cancer

    FromBreastcancer.org Podcast

    ratings:
    Length:
    23 minutes
    Released:
    Sep 28, 2022
    Format:
    Podcast episode

    Description

    At the European Society for Medical Oncology Congress 2022, Dr. Matthew Goetz presented interim overall survival results from the MONARCH 3 study showing that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer.
    Listen to the podcast to hear Dr. Goetz explain:

    how Verzenio works

    the aims of MONARCH 3 study

    the difference between progression-free and overall survival and why each is important

    Verzenio side effects

    what the results mean for people diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer
    Released:
    Sep 28, 2022
    Format:
    Podcast episode

    Titles in the series (100)

    Breastcancer.org is a nonprofit organization dedicated to providing the most reliable, complete, and up-to-date information about breast cancer. Our mission is to help women and their loved ones make sense of the complex medical and personal information about breast cancer, so they can make the best decisions for their lives. Breastcancer.org podcasts offer unique insights on prevention, treatment, research, and other breast cancer topics from our medical experts and invited guests.